Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 10/2012

01-10-2012 | Original paper

Significant calendar period deviations in testicular germ cell tumors indicate that postnatal exposures are etiologically relevant

Authors: Crystal Speaks, Katherine A. McGlynn, Michael B. Cook

Published in: Cancer Causes & Control | Issue 10/2012

Login to get access

Abstract

Purpose

The current working model of type II testicular germ cell tumor (TGCT) pathogenesis states that carcinoma in situ arises during embryogenesis, is a necessary precursor, and always progresses to cancer. An implicit condition of this model is that only in utero exposures affect the development of TGCT in later life. In an age-period-cohort analysis, this working model contends an absence of calendar period deviations. We tested this contention using data from the SEER registries of the United States.

Methods

We assessed age-period-cohort models of TGCTs, seminomas, and nonseminomas for the period 1973–2008. Analyses were restricted to whites diagnosed at ages 15–74 years. We tested whether calendar period deviations were significant in TGCT incidence trends adjusted for age deviations and cohort effects.

Results

This analysis included 32,250 TGCTs (18,475 seminomas and 13,775 nonseminomas). Seminoma incidence trends have increased with an average annual percentage change in log-linear rates (net drift) of 1.25 %, relative to just 0.14 % for nonseminoma. In more recent time periods, TGCT incidence trends have plateaued and then undergone a slight decrease. Calendar period deviations were highly statistically significant in models of TGCT (p = 1.24−9) and seminoma (p = 3.99−14), after adjustment for age deviations and cohort effects; results for nonseminoma (p = 0.02) indicated that the effects of calendar period were much more muted.

Conclusion

Calendar period deviations play a significant role in incidence trends of TGCT, which indicates that postnatal exposures are etiologically relevant.
Appendix
Available only for authorised users
Literature
1.
2.
Skakkebaek NE, Berthelsen JG, Muller J (1982) Carcinoma-in situ of the undescended testis. Urol Clin North Am 9(3):377–385PubMed
3.
Sonne SB, Almstrup K, Dalgaard M, Juncker AS, Edsgard D, Ruban L, Harrison NJ, Schwager C, Abdollahi A, Huber PE, Brunak S, Gjerdrum LM, Moore HD, Andrews PW, Skakkebaek NE, Rajpert-De Meyts E, Leffers H (2009) Analysis of gene expression profiles of microdissected cell populations indicates that testicular carcinoma in situ is an arrested gonocyte. Cancer Res 69(12):5241–5250. doi:10.​1158/​0008-5472.​CAN-08-4554 PubMedCrossRef
4.
Oosterhuis JW, Kersemaekers AM, Jacobsen GK, Timmer A, Steyerberg EW, Molier M, Van Weeren PC, Stoop H, Looijenga LH (2003) Morphology of testicular parenchyma adjacent to germ cell tumours. An interim report. APMIS 111(1):32–40 (discussion 41-32)PubMedCrossRef
5.
von der Maase H, Rorth M, Walbom-Jorgensen S, Sorensen BL, Christophersen IS, Hald T, Jacobsen GK, Berthelsen JG, Skakkebaek NE (1986) Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed) 293(6559):1398–1401CrossRef
6.
Skakkebaek NE (1978) Carcinoma in situ of the testis: frequency and relationship to invasive germ cell tumours in infertile men. Histopathology 2(3):157–170PubMedCrossRef
7.
Giwercman A, Skakkebaek NE (1993) Carcinoma in situ of the testis: biology, screening and management. Eur Urol 23(Suppl 2):19–21PubMed
8.
Aalen OO, Tretli S (1999) Analyzing incidence of testis cancer by means of a frailty model. Cancer Causes Control 10(4):285–292PubMedCrossRef
9.
Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Moller H (2006) Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 118(12):3099–3111PubMedCrossRef
10.
Moller H (1989) Decreased testicular cancer risk in men born in wartime. J Natl Cancer Inst 81(21):1668–1669PubMedCrossRef
11.
McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE (2003) Trends in the incidence of testicular germ cell tumors in the United States. Cancer 97(1):63–70PubMedCrossRef
12.
13.
Bray F, Richiardi L, Ekbom A, Forman D, Pukkala E, Cuninkova M, Moller H (2006) Do testicular seminoma and nonseminoma share the same etiology? Evidence from an age-period-cohort analysis of incidence trends in eight European countries. Cancer Epidemiol Biomarkers Prev 15(4):652–658PubMedCrossRef
14.
Liu S, Wen SW, Mao Y, Mery L, Rouleau J (1999) Birth cohort effects underlying the increasing testicular cancer incidence in Canada. Can J Public Health 90(3):176–180PubMed
15.
Richiardi L, Bellocco R, Adami HO, Torrang A, Barlow L, Hakulinen T, Rahu M, Stengrevics A, Storm H, Tretli S, Kurtinaitis J, Tyczynski JE, Akre O (2004) Testicular cancer incidence in eight northern European countries: secular and recent trends. Cancer Epidemiol Biomarkers Prev 13(12):2157–2166PubMed
16.
Liu S, Semenciw R, Waters C, Wen SW, Mery LS, Mao Y (2000) Clues to the aetiological heterogeneity of testicular seminomas and non-seminomas: time trends and age-period-cohort effects. Int J Epidemiol 29(5):826–831PubMedCrossRef
17.
18.
Moller H (2001) Trends in incidence of testicular cancer and prostate cancer in Denmark. Hum Reprod 16(5):1007–1011PubMedCrossRef
19.
20.
21.
22.
23.
24.
Fritz AG (2000) International classification of diseases for oncology: ICD-O, 3rd edn. World Health Organization, Geneva
25.
World Health Organization (2004) Pathology and genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon, Oxford University Press [distributor], Oxford
26.
27.
Holford TR (1983) The estimation of age, period and cohort effects for vital rates. Biometrics 39(2):311–324PubMedCrossRef
28.
Clayton D, Schifflers E (1987) Models for temporal variation in cancer rates II: Age-period-cohort models. Stat Med 6(4):469–481PubMedCrossRef
29.
Robertson C, Gandini S, Boyle P (1999) Age-period-cohort models: a comparative study of available methodologies. J Clin Epidemiol 52(6):569–583PubMedCrossRef
30.
31.
32.
Lerro CC, McGlynn KA, Cook MB (2010) A systematic review and meta-analysis of the relationship between body size and testicular cancer. Br J Cancer 103(9):1467–1474PubMedCrossRef
33.
McGlynn KA, Cook MB (2009) The epidemiology of testicular cancer. In: Cooney KA, Foulkes WD (eds) Male reproductive cancers: epidemiology, pathology and genetics, vol Cancer Genetics series. Springer Publications, New York
34.
Daling JR, Doody DR, Sun X, Trabert BL, Weiss NS, Chen C, Biggs ML, Starr JR, Dey SK, Schwartz SM (2009) Association of marijuana use and the incidence of testicular germ cell tumors. Cancer 115(6):1215–1223. doi:10.​1002/​cncr.​24159 PubMedCrossRef
35.
36.
Pettersson A, Richiardi L, Nordenskjold A, Kaijser M, Akre O (2007) Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med 356(18):1835–1841PubMedCrossRef
37.
Wanderas EH, Tretli S, Fossa SD (1995) Trends in incidence of testicular cancer in Norway 1955–1992. Eur J Cancer 31A(12):2044–2048PubMedCrossRef
38.
39.
Zippin C, Lum D, Hankey BF (1995) Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 76(11):2343–2350PubMedCrossRef
40.
Metadata
Title
Significant calendar period deviations in testicular germ cell tumors indicate that postnatal exposures are etiologically relevant
Authors
Crystal Speaks
Katherine A. McGlynn
Michael B. Cook
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 10/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0036-5

Other articles of this Issue 10/2012

Cancer Causes & Control 10/2012 Go to the issue

Original paper

Erythrocyte membrane fatty acid composition, serum lipids, and non-Hodgkin’s lymphoma risk in a nested case–control study: the multiethnic cohort

Original Paper

Green and black tea intake in relation to prostate cancer risk among Singapore Chinese

Original paper

Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy

Original Paper

Meat intake and risk of non-Hodgkin lymphoma

Original paper

Gallbladder cancer, a vanishing disease?

Original paper

ADRB2 G–G haplotype associated with breast cancer risk among Hispanic and non-Hispanic white women: interaction with type 2 diabetes and obesity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits